How long do you need to take Lenvatinib/Lenvatinib before you can consider stopping it?

The treatment cycle of Lenvatinib/Lenvatinib (Lenvatinib) does not have a uniform “fixed course”, and its length of use mainly depends on the patient’s tumor type, efficacy response, adverse reactions, and combination treatment mode. As a targeted anticancer drug, lenvatinib is usually used continuously for a long time until disease progression or intolerable toxicity occurs. This means that as long as the drug is still effective for the patient and the side effects can be controlled, doctors generally recommend continued use, rather than setting a specific time limit for taking the drug and then forcing it to stop.

This "maintenance treatment" strategy is especially suitable for patients with hepatocellular carcinoma or differentiated thyroid cancer. On the premise that the tumor burden is significantly controlled and imaging evaluation shows that the disease is stable or shrinking, continued treatment can significantly extend the progression-free survival. However, if serious toxic and side effects occur during treatment, especially if high blood pressure cannot be controlled, abnormal heart function, significant deterioration of liver and kidney function, or severe fatigue, the doctor may recommend reducing the dosage or even suspending use. Some patients have significant tumor shrinkage or partial remission after a period of treatment. At this time, it can also be evaluated whether it is appropriate to discontinue the drug intermittently, but this requires careful decision-making and usually requires multiple imaging evaluations and the judgment of a professional oncologist.

It is worth noting that even in the stage of disease remission, premature discontinuation of medication may lead to disease rebound or rapid progression. Therefore, whether to discontinue medication should be based on clinical judgment of "risks and benefits" rather than subjective speculation or time limits. In the treatment of specific tumors, such as kidney cancer or liver cancer, lenvatinib is also used in combination with immune checkpoint inhibitors such as pembrolizumab. The timing of discontinuation is more complicated and needs to be considered comprehensively based on the response of the two drugs.

Reference materials:https://www.lenvima.com/